Pioneering the development
of engineered IgM antibodies
NEWS
IGM Announces Pricing of Upsized $200 million Public Offering
IGM Announces Proposed Public Offering
IGM Biosciences to Present at Three Upcoming Investor Conferences
PRESENTATIONS & PUBLICATIONS
At the Intersection of Science and Engineering: Novel Platform Approach to Immunotherapy with IGM-2323
ESMO Immuno-Oncology Virtual Congress 2020 – December 9-12, 2020 Educational Session: Novel Immunotherapeutic Platforms – December 11, 2020
The Anti-Tumor Activity of IGM-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML
62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents Abstract Number: 2093, December 6, 2020
ASH 2020 Investor Conference Call: Pioneering the Development of Engineered IgM Antibodies
IGM Investor Conference Call Presentation at the 62nd ASH Annual Meeting and Exposition December 5, 2020
Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
62nd American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2020 Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies Number: 1142, December 5,…
Agonist IgM: Anti-Death Receptor 5 IgM Induces Tumor Cell Apoptosis in vitro and in vivo with a Favorable Safety Profile
PEGS Europe Virtual – November 12, 2020 Program: Novel Targets and Emerging Therapeutic Areas
Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?
PEGS Europe Virtual – November 12, 2020 Programs: Keynote Presentation in Novel Targets and Emerging Therapeutic Areas & in Engineering Bispecific Antibodies
Immunologic Mechanisms and Engineering Objectives: Case Study of Anti-PD-L1 x IL-15
PEGS Europe Virtual – November 11, 2020 Program: Advancing Bispecifics and Combination Therapy to the Clinic
Abstract: Targeting IL-15 delivery to PD-L1 Expressing Tumors with an Anti-PD-L1-IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity
Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020
Poster: Targeting IL-15 delivery to PD-L1 Expressing Tumors using an Anti-PDL1 x IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity
Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs – November 10-15, 2020
Abstract 1142: Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies
The 62nd ASH Annual Meeting and Exposition – December 5-8, 2020